论文部分内容阅读
作者将手术后存活30天的231例患者,根据日本胃癌研究协会对胃癌研究的标准,根据组织学分成Ⅰ期-Ⅳ期,再分成输血组与未输血组。排除由癌症进展情况不同而引起的差异,观察每组术后1-5年累积存活率。将Ⅰ期患者分成术后辅助免疫化疗和不用任何治疗的两组,观察输血与术后辅助免疫化学疗法或胃癌组织学分型之间的相关性。比较各相应组输血与未输血患者的5年存活率。用Cutler和Edere′s的寿命表方法计算累积存活率。试验结果,术后5年存活率输血组明显低于未输血组(P<0.002)。输血对各期癌症累积存活率的影响,术后各年中输血组的存活率低于未输血组,I
The authors of the 231 patients who survived 30 days after surgery were divided into I-IV stages according to histological criteria according to the standards of the Gastric Cancer Research Association of Japan, and were divided into blood transfusion groups and non-blood transfusion groups. Excluding the differences caused by the different cancer progression conditions, the cumulative survival rate of 1-5 years after each group was observed. The patients of stage I were divided into two groups after adjuvant immunochemotherapy and without any treatment. The correlation between blood transfusion and postoperative adjuvant immunochemotherapy or histological type of gastric cancer was observed. The 5-year survival rate of patients in each group with and without blood transfusion was compared. The cumulative survival rate was calculated using Cutler and Edere’s life table methods. As a result of the test, the 5-year survival rate in the transfusion group was significantly lower than that in the non-transfusion group (P<0.002). The effect of blood transfusion on the cumulative survival rate of various stages of cancer, the survival rate of the blood transfusion group in each postoperative year was lower than that of the non-transfusion group, I